Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT-15: Nintedanib as second-line therapy in FGFR1-amplified NSCLC
2013-004324-11Phase 2Active
- Sponsor
- NVALT
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in non-small cell lung cancer (NSCLC), sponsored by NVALT. Primary endpoint: Progression-free survival. Started Mar 2014; status: active.
02
Drugs
nintedanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-004324-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004324-11.